The multifaceted anti-atherosclerotic properties of herbal flavonoids: A comprehensive review by Meiwen Huang, Xuena Xie, Rong Yuan, Qiqi Xin, Shudong Ma, Hongai Guo, Yu Miao, Chunyu Hu, Yizhun Zhu, Weihong Cong

“…Currently, the clinical management of AS relies predominantly on statins and proprotein convertase subtilisin/kexin type 9 inhibitors, which primarily aim to reduce low-density lipoprotein levels and have demonstrated some therapeutic efficacy. …”
Get full text

Real-world treatment patterns of patients with acute coronary syndrome based on 15-year data by Inga S. Egorova, Natalia N. Vezikova

“…Analysis of drug therapy for ACS showed that aspirin was prescribed in 8 255 (98.9%), β-blockers in 7 671 (91.9%), and statins in 8 138 (97.5%) cases. Life-threatening complications occurred in 1 out of 3 patients with STEACS and 1 out of 7 patients with NSTE-ACS. …”
Get full text

Efficacy of an intervention to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease: a study protocol for a randomized controlled trial by Francisco Manuel Lidón-Muñoz, José Antonio Quesada, José Antonio Quesada, José Antonio Quesada, Vicente Francisco Gil-Guillén, Vicente Francisco Gil-Guillén, Vicente Francisco Gil-Guillén, Domingo Orozco-Beltrán, Domingo Orozco-Beltrán, Domingo Orozco-Beltrán

“…Secondary prevention is effective for patients with a history of cardiovascular events, with antihypertensives, statins, and acetylsalicylic acid being the most prescribed drugs. …”
Get full text

Strategies to Improve Health Care Provider Prescription of and Patient Adherence to Guideline-Recommended Cardiovascular Medications for Atherosclerotic Occlusive Disease: Protocol... by Aidan M Kirkham, Dean A Fergusson, Justin Presseau, Daniel I McIsaac, Risa Shorr, Derek J Roberts

“… BackgroundIn patients with atherosclerotic occlusive diseases, systematic reviews and meta-analyses of randomized controlled trials (RCTs) report that antiplatelets, statins, and antihypertensives reduce the risk of major adverse cardiac events, need for revascularization procedures, mortality, and health care resource use. …”
Get full text

Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Le... by Hammoudeh AJ, Aldalal’ah M, Smadi EA, Alrishoud D, Alomari A, Alkhawaldeh M, Rizik A, Okour MF, Araydah M

“…SMuRF-less patients were less likely to receive secondary prevention cardiovascular medications (antiplatelet agents, statins, renin angiotensin blockers and beta blockers); all p < 0.001. …”
Get full text

Lower Extremity Peripheral Arterial Disease Is an Independent Predictor of Coronary Heart Disease and Stroke Risks in Patients with Type 2 Diabetes Mellitus in China by Xiao-Hong Pang, Jue Han, Wan-Lan Ye, Xue Sun, Yue Ding, Wen-Juan Huang, Yi-Ming Zhao, Han-Yu Lou, Li-Zhen Shan, Ying-Xiu Kang, Xiao-Xiao Song, Song-Zhao Zhang, Wei Gu, Peng-Fei Shan

“…Age; duration of diabetes; systolic blood pressure; the hypertension rate; the use of hypertension drugs, ACEI /ARB, and statins; CHD risk; fatal CHD risk; stroke risk; and fatal stroke risk were significantly higher in the PAD group than in the non-PAD group (P<0.05 for all). …”
Get full text

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and me... by Maciej Banach, Martyna Fronczek, Tadeusz Osadnik, Agnieszka Gach, Dominik Strapagiel, Marcin Słomka, Mateusz Lejawa, Anna Goc, Ewa Boniewska-Bernacka, Anna Pańczyszyn, Gregory Y.H. Lip, Dimitri P. Mikhailidis, Peter P. Toth, Peter E. Penson, Jacek Jóźwiak

“…Using the developed PRS scale and biochemical analyses, we will assess the effectiveness of lipid-lowering therapy with statins in patients with high and low genetic risk of sudden CVD events (secondary endpoints). …”
Get full text

HIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature by Dimitra P. Vageli, Panagiotis G. Doukas, Dimitrios Georgiou, Michailangelos P. Prokopiou, Nefeli E. Ladaki, Androniki Papadopoulou, Sotirios G. Doukas, Konstantina Zacharouli, Konstantinos P. Makaritsis, Maria Ioannou

“…HIF-1α/VEGF immunophenotypes reflect atherosclerosis treatment efficacy using, among others, HIF-inhibitors, statins, polyphenols, miR-497-5p, methylation modification, adenosine receptor antagonists, natural products, or glycosides. …”
Get full text

Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment by Joon‐Tae Kim, Ji Sung Lee, Hyunsoo Kim, Beom Joon Kim, Jihoon Kang, Keon‐Joo Lee, Jong‐Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae‐Kwan Cha, Dae‐Hyun Kim, Tai Hwan Park, Kyungbok Lee, Jun Lee, Keun‐Sik Hong, Yong‐Jin Cho, Hong‐Kyun Park, Byung‐Chul Lee, Kyung‐Ho Yu, Mi Sun Oh, Dong‐Eog Kim, Jay Chol Choi, Jee‐Hyun Kwon, Wook‐Joo Kim, Dong‐Ick Shin, Kyu Sun Yum, Sung Il Sohn, Jeong‐Ho Hong, Sang‐Hwa Lee, Man‐Seok Park, Wi‐Sun Ryu, Kwang‐Yeol Park, Juneyoung Lee, Jeffrey L. Saver, Hee‐Joon Bae

“…Using a large stroke registry, we investigated whether 2 commonly used statins, rosuvastatin and atorvastatin, differ in their effectiveness in reducing the risk of vascular events in patients with acute ischemic stroke. …”
Get full text

Cost-utility analysis of combination medical therapies in chronic coronary syndrome: a comparative study using real-world and patient-level data from Iran by Fatemeh Soleymani, Parham Sadeghipour, Majid Davari, Abbas Kebriaeezadeh, Behzad Fatemi, Mohammad Reza Maracy, Nasim Naderi, Saman Zartab

“…Ultimately, taking into account the sample size and study power, a comparison was made between the combination therapy of β-blockers (BB), long-acting nitroglycerin (LAN), aspirin (ASA) and statin versus the group receiving only BB, ASA and statin.Primary and secondary outcome measures The primary outcome measure was the incremental cost-effectiveness ratio, along with an initial evaluation of disability-adjusted life-years (DALYs) and costs related to the interventions.Results The BB/LAN/ASA/statin combination was cost-saving and effective, averting 0.02 DALYs and saving $172 compared with BB/ASA/statin. …”
Get full text

Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies by Lucile Musset, Makoto Miyara, Olivier Benveniste, Jean-Luc Charuel, Alexander Shikhman, Olivier Boyer, Richard Fowler, Andrew Mammen, Joe Phillips, Michael Mahler

“…Anti-HMGCR antibodies are not always associated with the use of statin and appear to be the exclusive autoantibody specificity in patients with statin associated myopathies.…”
Get full text

Real-world evaluation of select adverse drug reactions and healthcare utilization associated with parenteral Ibuprofen and ketorolac in adult and pediatric patients by Mosadoluwa Afolabi, Jensy Rodriguez-Silva, Ishveen Chopra, Ines Macias-Perez, Jason Makii, Emily Durr, Theresa Human

Get full text

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes by Anan Huang, Xin Qi, Liping Wei, Mingyin Zhang, Shiqi Zhou

“…High level of non-HDL-c/TC presented an excellent prognostic value compared with other lipid-related markers in CAD patients treated with statin.…”
Get full text

Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cv... by Satoshi Shoji, Nishant P. Shah, Peter Shrader, Laine E. Thomas, Jonathan D. Arnold, Nafeesa N. Dhalwani, Neena A. Thomas, Bethany Kalich, Elisa L. Priest, Mahanaz Syed, Cezary Wójcik, Eric D. Peterson, Ann Marie Navar

“…Overall, 76.0 % of patients were on statin, 40.5 % were on a high-intensity statin and only 5.8 % were on a statin in combination with ezetimibe or a PCSK9i monoclonal antibody. …”
Get full text

Muscle contractile properties and perceived fatigue in the general and diseased population by Isa H. Mast, Neeltje A. E. Allard, Dominique tenHaaf, Anouk A. F. Stoffels, Lando Janssen, Hieronymus W. H. vanHees, Silvie Timmers, Bregina T. P. Hijmans‐Kersten, Maria T. E. Hopman, Laurien M. Buffart

“…To conclude, contractile properties were impaired in patients with COPD and statin users. Associations between contractile properties and perceived fatigue varied across populations. …”
Get full text

Myopathy with Concurrent Tadalafil and Simvastatin by Maria Pia Gargante, Marco Vacante, Cristina Russo, Mariano Malaguarnera

“…A 48-year-old man, using statin, was admitted to hospital with progressive myalgia after consumption of tadalafil and simvastatin. …”
Get full text

Factors Associated with Goal Achievement in Patients with Dyslipidemia in Primary Care by Pinto-González, Gustavo, Uribe-Velez, Natalia Andrea, Quirós-Gómez, Oscar Iván

“…Sociodemographic variables, comorbidities, cardiovascular risk categories, and statin use were included. Binomial regression was performed to obtain crude prevalence ratios (PR), and a multivariate model was used to determine variables associated with achieving LDL goals, represented by adjusted prevalence ratios (aPR). …”
Get full text

Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement by Gary J. Martin, Meron Teklu, Edwin Mandieka, Joe Feinglass

“…At follow-up, 87.8% of patients were prescribed a statin, 9.7% were on ezetimibe, and 0.5% were on a PCSK9 inhibitor. …”
Get full text

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropoplite... by Chiu-Yang Lee

“…Kaplan–Meier curve analyses of time-to-primary cumulative AFS showed that nondiabetes mellitus, mild PAD, and cilostazol and statin treatment were correlated with a superior 3-year AFS (log rank test, P=0.001, P<0.001, P=0.009, and P=0.044, respectively). …”
Get full text

Gene Expression of Adhesion Molecules in Endothelial Cells from Patients with Peripheral Arterial Disease Is Reduced after Surgical Revascularization and Pharmacological Treatment by Franca Marino, Luigina Guasti, Matteo Tozzi, Laura Schembri, Luana Castiglioni, Elisabetta Molteni, Gabriele Piffaretti, Patrizio Castelli, Marco Cosentino

“…Patients were longitudinally evaluated 1 month before surgery, when statin treatment was established, at the time of surgery, and after 2 and 5 months. …”
Get full text